Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) PE Ratio: 279.07 (As of Jul. 21, 2026) — 100% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688796 Biocytogen Pharmaceuticals (Beijing) Co Ltd SHSE:688796
52 GF Score
Price ¥120.00
GF Value ¥74.57
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Biocytogen Pharmaceuticals (Beijing) Co PE Ratio?

Biocytogen Pharmaceuticals (Beijing) Co SHSE:688796 -0.65% 52 PE Ratio is 279.07 as of Jul. 21, 2026, which is 100% above its 10-year median of 139.88. GuruFocus rates SHSE:688796 with a GF Score™ of 52/100 and a GF Value™ of ¥74.57 (Significantly Overvalued). The stock has 2 warning signs investors should review.

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-21), Biocytogen Pharmaceuticals (Beijing) Co's share price is ¥120.00. Biocytogen Pharmaceuticals (Beijing) Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was ¥0.43. Therefore, Biocytogen Pharmaceuticals (Beijing) Co's PE Ratio for today is 279.07.

During the past 6 years, Biocytogen Pharmaceuticals (Beijing) Co's highest PE Ratio was 412.71. The lowest was 73.14. And the median was 139.88.

Biocytogen Pharmaceuticals (Beijing) Co's EPS (Diluted) for the six months ended in Dec. 2025 was ¥0.31. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was ¥0.43.

As of today (2026-07-21), Biocytogen Pharmaceuticals (Beijing) Co's share price is ¥120.00. Biocytogen Pharmaceuticals (Beijing) Co's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was ¥0.42. Therefore, Biocytogen Pharmaceuticals (Beijing) Co's PE Ratio without NRI ratio for today is 283.02.

During the past 6 years, Biocytogen Pharmaceuticals (Beijing) Co's highest PE Ratio without NRI was 407.91. The lowest was 74.39. And the median was 138.26.

Biocytogen Pharmaceuticals (Beijing) Co's EPS without NRI for the six months ended in Dec. 2025 was ¥0.31. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was ¥0.42.

During the past 12 months, Biocytogen Pharmaceuticals (Beijing) Co's average EPS without NRI Growth Rate was 443.00% per year.

During the past 6 years, Biocytogen Pharmaceuticals (Beijing) Co's highest 3-Year average EPS without NRI Growth Rate was -1.70% per year. The lowest was -1.70% per year. And the median was -1.70% per year.

Biocytogen Pharmaceuticals (Beijing) Co's EPS (Basic) for the six months ended in Dec. 2025 was ¥0.31. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was ¥0.43.

Back to Basics: PE Ratio


Biocytogen Pharmaceuticals (Beijing) Co  (SHSE:688796) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Biocytogen Pharmaceuticals (Beijing) Co PE Ratio Related Terms


Biocytogen Pharmaceuticals (Beijing) Co PE Ratio Historical Data

* Premium members only.

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocytogen Pharmaceuticals (Beijing) Co PE Ratio Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio
Get a 7-Day Free Trial N/A N/A N/A 99.06 74.82

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only At Loss At Loss 99.06 At Loss 74.82

SHSE:688796 vs VRTX, REGN, ALNY: PE Ratio Comparison

For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocytogen Pharmaceuticals (Beijing) Co PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocytogen Pharmaceuticals (Beijing) Co's PE Ratio distribution charts can be found below:

* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's PE Ratio falls into.


SHSE:688796
52GF Score
Biocytogen Pharmaceuticals (Beijing) Co Ltd SHSE:688796
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biocytogen Pharmaceuticals (Beijing) Co PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Biocytogen Pharmaceuticals (Beijing) Co's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=120.00/0.430
=279.07

Biocytogen Pharmaceuticals (Beijing) Co's Share Price of today is ¥120.00.
For company reported semi-annually, Biocytogen Pharmaceuticals (Beijing) Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was ¥0.43.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio →
What does a PE Ratio of 279.07 mean?
Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) has a PE Ratio of 279.07 as of Jul. 21, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. This is 100% above median its historical median of 139.88. Over the past decade, Biocytogen Pharmaceuticals (Beijing) Co's PE Ratio has ranged from 73.14 to 412.71.
Is Biocytogen Pharmaceuticals (Beijing) Co's PE Ratio too high?
Biocytogen Pharmaceuticals (Beijing) Co's current PE Ratio of 279.07 is 100% above median its 10-year median of 139.88. Over the past 10 years, this metric has ranged from a low of 73.14 to a high of 412.71. Overall, Biocytogen Pharmaceuticals (Beijing) Co has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocytogen Pharmaceuticals (Beijing) Co's PE Ratio compare to VRTX and REGN?
Biocytogen Pharmaceuticals (Beijing) Co's PE Ratio of 279.07 can be compared against companies in the Biotechnology industry. Historically, Biocytogen Pharmaceuticals (Beijing) Co's own PE Ratio has ranged from 73.14 to 412.71 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for a Biotechnology company?
A good PE Ratio depends on the Biotechnology industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. Biocytogen Pharmaceuticals (Beijing) Co's current PE Ratio is 279.07, which is 100% above median its own 10-year median of 139.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocytogen Pharmaceuticals (Beijing) Co stock overvalued right now?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥74.57, compared to a current price of ¥120.00 — trading 60.9% above its estimated fair value. The current PE Ratio is 279.07, which is 100% above median its 10-year median of 139.88. Biocytogen Pharmaceuticals (Beijing) Co's overall GF Score™ is 52/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796), the current PE Ratio is 279.07 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) Overvalued in 2026?

Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co stock appears to be overvalued. The current stock price of ¥120.00 is trading 60.9% above its estimated GF Value™ of ¥74.57. GuruFocus considers Biocytogen Pharmaceuticals (Beijing) Co to be Significantly Overvalued.

Key valuation signals for SHSE:688796:

  • PE Ratio: 279.07 (100% above median its 10-year median of 139.88)
  • GF Value™: ¥74.57 vs. price of ¥120.00 (60.9% above fair value)
  • GF Score™: 52/100 with 2 warning signs

No single metric tells the full story. See the SHSE:688796 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biocytogen Pharmaceuticals (Beijing) Co Business Description

Other Exchanges 02315:Hong KongI54:Germany
Address 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
52GF Score

Get the complete analysis for SHSE:688796

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥120.00
Price
¥74.57
GF Value